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Abstract
Like other emerging economies, India’s quest for independent, evidence-based, and affordable 
healthcare has led to robust and promising growth in the clinical research sector, with a compound 
annual growth rate (CAGR) of 20.4% between 2005 and 2010. However, while the fundamental 
drivers and strengths are still strong, the past few years witnessed a declining trend (CAGR 
−16.7%) amid regulatory concerns, activist protests, and sponsor departure. And although India 
accounts for 17.5% of the world’s population, it currently conducts only 1% of clinical trials.
Indian and international experts and public stakeholders gathered for a 2-day conference in June 
2013 in New Delhi to discuss the challenges facing clinical research in India and to explore 
solutions. The main themes discussed were ethical standards, regulatory oversight, and 
partnerships with public stakeholders. The meeting was a collaboration of AAHRPP (Association 
for the Accreditation of Human Research Protection Programs)—aimed at establishing responsible 
and ethical clinical research standards—and PARTAKE (Public Awareness of Research for 
Therapeutic Advancements through Knowledge and Empowerment)—aimed at informing and 
engaging the public in clinical research.
The present article covers recent clinical research developments in India as well as associated 
expectations, challenges, and suggestions for future directions. AAHRPP and PARTAKE provide 
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etiologically based solutions to protect, inform, and engage the public and medical research 
sponsors.
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Introduction
In June 2013, a group of local and international clinical research and public stakeholders 
gathered in New Delhi to tackle a unique challenge: the fortunes and prospects of clinical 
research in India, one of the most promising global clinical research environments, appeared 
to be in decline. Conference stakeholders included experts from industry, academia, 
regulatory bodies, and the private sector as well as representatives from patient advocacy 
and public activist groups, non-governmental organizations (NGO’s), and the media. The 
scope of the representation was a reflection of the organizers’ collective belief that medical 
research in general and clinical research in particular require collaboration of both 
professional and non-professional segments of society, a rare undertaking in usual practice, 
to understand the challenges facing the sector and to identify effective solutions.
Background
Clinical research in India
Motivation for global and Indian clinical research—India has powerful drivers and 
attractive capabilities favoring clinical research. Rapid increase in life expectancy along 
with increases in the prevalence and burden of chronic illness are not yet matched by the 
provisions of the healthcare system or indigenous medical research capabilities [1–3]. The 
aspirations of the rapidly emerging economy, on track to become the world’s second-largest 
by 2050, indeed include becoming self-sufficient in providing care to its growing population 
and basing such care on home-grown, evidence-based research [4]. Ethnic differences in the 
genetically heterogeneous population may affect presentation and outcomes of interventions, 
making generalizations from studies done elsewhere difficult and providing a strong case for 
indigenous clinical research [2,5–8].
India offers many advantages likely to appeal to medical researchers: well-trained (including 
many returning, Western-trained) physicians and investigators, an English-speaking 
environment, treatment-naïve populations, large healthcare center catchment areas, access to 
world-class information technologies and data management infrastructure, competitive 
operational costs (40–60% reduction when compared with Western sites), and sustained 
economic growth [9]. A study in 2006 by Kearney found India second only to China on the 
Country Attractiveness Index for Clinical Trials (primarily on the basis of patient pool and 
cost efficiency); however, India was less attractive than most countries in terms of 
regulatory conditions, infrastructure, and environmental factors (Figure 1) [10]. Advantages 
also include a harmonized regulatory system with an auditable clinical trial registry [11]. In 
addition, collaboration with Western universities and research networks has contributed to 
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the establishment of high clinical research standards [12,13]. Notwithstanding the 
considerable potential and strengths, and after a 2003 regulatory overhaul (Schedule Y [14]) 
initially translating into robust growth (2005–2010), the clinical research sector has 
witnessed a decline in recent years (Figure 2) [15–19]. While India represents 17.5% of the 
world’s population, it has conducted only 1.75% of the world’s clinical trials (2749 of 
157,327) and currently only conducts 1.08% of global trials (211 of 19,599 trials registered 
with ClinicalTrials.gov from January 1 to December 31, 2013) [20–21].
India’s regulatory environment
The Indian clinical research environment has come under increased scrutiny by public 
activists and the media, and subsequently by the Indian Supreme Court for perceived 
unethical practices in the conduct of clinical trials (Table 1) [16,24,26,30,32,36–39]. A 
report by the Indian Parliamentary Standing Committee identified an understaffed and 
under-resourced Central Drugs Standard Control Organization (CDSCO), including 
deficiencies in enforcing regulations, “collusion” with industry sponsors, and claims of 
exploitation of Indian citizens by foreign pharmaceutical companies [40]. Lack of regulatory 
clarity and lengthy turnaround times for clinical trial approvals have deterred both local and 
foreign sponsors from conducting clinical trials in India and may have contributed to the 
reduction in the number of clinical trials in India since 2010 (Figure 2) [18,39]. On January 
30, 2013, the Ministry of Health and Family Welfare of India issued an amendment to the 
Drugs and Cosmetics Act of 1940 and the Ministry of Law issued a set of guidelines on 
patient compensation that included the need to pay should an experimental drug fail to show 
the intended therapeutic benefit (including in cases where research participants are allocated 
to placebo interventions) (Table 2) [25,30], Human Research Protection Program (HRPP) 
Conference, June 29–30, 2013, New Delhi, India].
In total, 169 participants, including 39 speakers, representing all clinical research 
stakeholders gathered for the 2-day conference. Fourteen participants were from the United 
States, the United Kingdom, Taiwan, and Saudi Arabia, and the rest were from India. The 
various attendees represented industry (56) healthcare (48), academia (40), NGO, public and 
patient advocacy (16), and regulatory (9) stakeholders.
Understanding the challenges and their causes
On day 1, conference participants viewed interactive and targeted presentations; on day 2, 
the group participated in focused discussions aimed at identifying and understanding the 
causes of challenges and proposing tangible solutions. Three factors and respective 
deficiencies emerged as probable causes of the observed difficulties facing clinical research 
in India:
Ethical standards of clinical research—Recent widespread reports of violations 
suggest that research standards, especially those pertaining to the protection of human 
participants, may not be properly enforced (Tables 1 and 2)
[19,22,23,26,33,34,36,38,40,41,48–50]. The responsibility of ensuring respect for and 
protection of study participants is the foundation of the partnership between the researcher 
and the human research participant. Several principles of importance have been identified as 
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essential to the ethical conduct of clinical trials: superiority of benefit over risk 
(beneficence), fairness in assignment and access (justice), and validity and freedom of bias 
(integrity) [51]. However, it is autonomy and respect, manifested in the adequacy of the 
informed-consent process and compensation for adverse outcomes, that appear to dominate 
the concerns of stakeholders [26,33,38,47].
Regulatory process—The regulatory system that governs clinical research in India has 
undergone significant revisions and acquired meaningful strengths in the first decade of the 
new millennium, including harmonization of global good clinical practice (GCP) regulations 
and the establishment of mandatory clinical trial registration [9,11,14]. In recent years, 
however, there have been numerous incidences of regulators having difficulty enforcing 
regulations due to inadequate staffing and resources, claims of industry bias, and lack of 
clarity and transparency (Tables 1 and 2) [39,40]. Criticism pointed to a lack of equitable 
and feasible regulations (e.g., determination of serious-adverse-event causality) that take 
into account sociocultural characteristics, diversity, and vulnerabilities [30,38,47]. There is 
also a need to ensure the quality of research training and conduct as well as compliance of 
investigators and research operators [13].
Public perceptions and engagement in clinical research—This encompasses the 
following:
Existence of cultural divides (professional, national, international) [12,16,24,49,52]
Impaired public awareness, comprehension, empowerment, engagement, and partnership in 
clinical research, with a substantial and an active portion of the population (15–25%) 
holding negative perceptions of clinical research and being distrustful of researchers and 
regulators [16].
Lack of transparency and impaired communication amongst professional and public 
stakeholders limits reconciliation of different perspectives and the ability to establish 
consensus, working relationships, and collaborations [53–55].
With holding important contributions that the public may provide as an active partner in the 
clinical research process (communicating therapeutic preferences; enhancing study design; 
helping with data collection; enforcing standards; and helping with research funding, 
lobbying, and public policy [53,54,56,57]).
While available data are not sufficient to establish causality, these recent challenges have 
been associated with a decline (−16.7% compound annual growth rate [CAGR]) in the 
number of clinical trials conducted in the 2010–2013 period after a promising growth of 
20.4% in the preceding 5 years (Figure 2).
Etiologically based solutions
Regulatory efforts together with the establishment of HRPPs and public awareness programs 
(e.g., PARTAKE [Public Awareness of Research for Therapeutic Advancements through 
Knowledge and Empowerment]) complement each other’s scope and strengths and offer 
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comprehensive, synergistic solutions to the complex problems facing clinical research in 
India.
Regulatory review and overhaul—Regulatory reorganization will ensure availability of 
resources and expertise to allow enforcement of regulations through education, training, 
accreditation, monitoring, and auditing of investigators and sites. Regulators should 
establish transparency and clarity regarding guidelines and responsibilities of clinical 
research professionals, and they should eliminate bias and conflicts of interest. The hoped 
outcomes of these actions are ensuring human research protection, verifying the quality of 
research applications and study operations, increasing trust in the regulatory system, 
reducing application turnaround times, and encouraging engagement and partnership by all 
stakeholders in clinical research. In the aggregate, these are also expected to lead to the 
generation of high-quality and credible research data.
Amendments proposed by regulators initially included provisions that were considered 
either not feasible or inconsistent with sound scientific methodology (e.g., compensation of 
all adverse events in clinical trials, expectation of therapeutic effect, attribution of placebo 
assignment to adverse events, expectation of ethics committees to determine compensation), 
yet these were decried by activists as containing insufficient protections for research 
participants [19,30,38,39]. By the end of 2013, the Chaudhury Expert Committee submitted 
recommendations that addressed earlier concerns [58].
ICMR (Indian Council of Medical Research), the national apex body to monitor clinical 
research in India is in the process of addressing clinical research challenges in India through 
collaboration with WHO (World Health Organization), Forum for Ethical Review 
Committees in the Asian & Western Pacific Region (FERCAP) and Strategic Initiative for 
Developing Capacity in Ethical Review (SIDCER).
HRPP initiatives—HRPP initiatives are a component of global AAHRPP (Association for 
the Accreditation of Human Research Protection Programs) efforts to promote responsible 
and ethical clinical research [59]. AAHRPP’s mission is to protect human participants and 
enhance research quality through an accreditation process. The process aims to establish 
high, harmonized, and consistent standards of research operations, including standards for 
investigators, study teams, institutions, and ethics committees involved in clinical research. 
The process starts with self-assessment of compliance with a set of objective standards 
followed by onsite evaluation and council review by AAHRPP staff. The process 
emphasizes ongoing education and training, continuous process improvement, performance-
based objective standards, and repeat accreditation. A robust informed-consent process (e.g., 
audio-video recording), monitoring, and auditing are examples of high standards that are 
involved. As of December 2013, India has 3 accredited institutions, China has 2, Singapore 
1, South Korea 6, Taiwan 1, Mexico 1, and several additional institutions from emerging 
economies are in the process of seeking AAHRPP accreditation [60].
AAHRPP standards are grouped into 3 domains (Table 3): I) organization; II) institutional 
review board or ethics committee; and III) researcher and research staff. Each standard is 
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further divided into elements that provide additional details on specific accreditation 
requirements [60].
PARTAKE—The PARTAKE initiative started in India and then expanded to the United 
States and China, where surveys are underway [16]. Public awareness, perceptions, and 
consequent attitudes toward clinical research may impact regulatory policies, guide research 
priorities, and shape growth in the sector; however, distrust, lack of awareness, and 
misconceptions of clinical research have been identified as key barriers to participation in 
clinical trials [61–65]. The PARTAKE initiative is based on the premise that an informed, 
participating public is invaluable for the following ethical, methodological, and operational 
reasons:
A. Ethical: These can be divided into rights and obligations.
Rights: Participants in clinical research have the right to make informed decisions about 
participation in research [49,66,67] and are better positioned to protect their rights when 
they are knowledgeable of clinical research [68,69].
Obligations: Societies who desire and demand advanced therapeutics and individuals who 
are willing recipients of innovative treatments have an implied obligation to be part of the 
process that develops and approves them (i.e., becoming active participants, partners, and 
contributors to the process [53,54,67]).
Methodological: A wide and representative sample of participants in clinical research is 
essential to ensure adequate generalization of the findings to the population at large [57,70]. 
Informed persons and research participants could assist in enforcement of research standards 
(ethical and methodological) and increase the quality of data generated.
Operational: A key obstacle to medical progress is the limited participation in clinical 
research. This makes research more costly and less powerful in detecting meaningful 
therapeutic effects, and it delays the arrival of new treatments to those who need them 
[57,65,71–73].
The PARTAKE program includes 7 steps (Table 4), of which the first 2 have been initiated. 
Results of a pilot survey (albeit being limited to 1 Indian metropolitan [16]) suggest that the 
Indian public is aware of some key features of clinical research (e.g., purpose, value, 
voluntary nature of participation) and supports clinical research in general but is unaware of 
other key features (e.g., compensation, confidentiality, protection of human participants) and 
exhibits some distrust in the conduct and reporting of clinical trials [16]. Challenges facing 
the initiative and proposed solutions are summarized in Table 5.
Conclusions and Future Directions
The clinical research environment in India is challenged by a complex interplay of 
sociocultural, regulatory, ethical, economic, and scientific factors likely representing similar 
dynamics in other emerging economies. In a meeting of public, activist, media, government, 
academia, and clinical research industry stakeholders, a comprehensive effort was 
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undertaken to examine the sources of the difficulties and propose solutions. The principles 
and direction of AAHRPP (participant protection) and PARTAKE (public awareness) 
programs were identified, together with a regulatory overhaul, as complementary, 
synergistic, and crucial to any meaningful and lasting solutions. Etiologically based 
proposed strategies were focused on improving regulatory oversight, establishing research 
participant protection programs, and enhancing public awareness, empowerment, and 
engagement in clinical research. Ensuring a robust informed-consent process, promoting 
investigator education, establishing clarity and transparency of regulations, establishing 
community advocates, and creating a research participant bill of rights were some of the 
activities proposed by conference participants. These solutions should be carried out in a 
manner that is cognizant and respectful of sociocultural customs, diversity, and 
vulnerabilities of the population. These insights may be relevant to other emerging 
economies like China and Brazil, which (like India) have experienced a rapid introduction of 
modern research, and are looking to establish indigenous clinical research and bring the 
promise of affordable medical research and healthcare to their people.
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Figure 1. 
Most Attractive Global Locations for the Conduct of all Clinical Trials Outside the United 
States: 2006.
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Figure 2. 
ClinicalTrials.gov. All India Clinical Trials 2002–2013
Data were obtained from ClinicalTrial.gov on January 9, 2014. Methods: “Advanced 
Search” option was used. “India” entered in “Country” field. “First Received” field was used 
to include dates “From 01/01/…. To 12/31/….” for each year from 2002 through 2013. 
Compound annual growth rate (CAGR) was used for the periods 2005–2010 and 2010–2013 
(years prior to 2005 were deemed to contain data that were not meaningful) using the 
formula:
V (t0): Start Value; V (tn): Finish Value; tn − t0 : Number of Years
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Table 1
Examples of Public Perception of Clinical Research in India.
Research
Element
Perceptions Source Potential Implications/Consequences
Negative
Human participation
“Human guinea pigs” Allahabad High 
Court [22]; 
PARTAKE survey 
[16]
Indians are exploited by foreign and rich industry 
entities for financial gain [23].
Exploitation of vulnerable 
populations (illiterate or 
impoverished) [24]
Petition of Supreme 
Court [25]
Clinical trial applications put “on hold” amid 
revision of the regulatory system [19]
Adverse events
Violation of “right to live” under 
the constitution
Allahabad High 
Court [22]
Proposal to prosecute trial-related adverse events 
under the Indian Penal Code
Unnecessary and exploitative Media [26]; activists; 
surveys [27]; 
government 
compensation 
committee [28]
Adverse events are always due to trial participation 
and therefore should be compensated for; hold on 
clinical trials; withdrawal of drugs with favorable 
benefit/risk ratios [29]
Placebo assignment Violation of the right to effective 
treatments
Government 
compensation 
scheme [30]
Proposal to compensate study participants for lack of 
therapeutic effect [30]
Informed consent The process is not “informed” and 
“consent” cannot be assumed; 
consequence of paternalistic model 
of health care [31]
National Human 
Rights Commission 
[32], media [33,34], 
activists, PARTAKE 
survey [16]
Addition of audio-visual recording to informed-
consent process [35]
Positive
Medical knowledge Enhancing public health Surveys [16,27] Large majority endorses research
Human participation
Voluntarism Surveys [16,27] Majority interested in participating in research
Altruism Surveys [16,27] Majority endorses altruism as the only valid 
motivation to participate in research
PARTAKE, Public Awareness of Research for Therapeutic Advancements through Knowledge and Empowerment.
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Table 2
Events Related to Standards of Clinical Research in India.
Event Description Impact Notes
Deaths in HPV vaccine 
study
4 teenage girls die during 
vaccine trial [41]
Foreign sponsors (Gates 
Foundation, PATH) blamed 
for using Indians as “guinea 
pigs” [41]
A government-commissioned committee 
confirmed the deaths were not related to the 
vaccine [41]
CDSCO report Government report finds 
deficiency in enforcement of 
regulation [40]
Activist protests, Supreme 
Court intervention, 
regulatory overhaul, hold on 
clinical trial approvals 
[18,19,30]
“Collusion” of regulators with industry 
sponsors is decried in the media; it is 
inferred by the identification of copycat 
letters sent by physician experts to the 
regulators in support of pharmaceutical 
clinical trial applications
NGO petitions Requesting inquiry into the 
small number of trial adverse 
events and deaths resulting in 
compensation [33]
Leading to Supreme Court 
January 2013 decision (see 
below)
Supreme Court decision Petitioned by activists to 
investigate compensation for 
trial-related adverse events 
and deaths
Regulatory overhaul; 3-
month hold on clinical trial 
application approval [19,25]
NIH trials in India “on 
hold”
June 2013 announcement 
amid perceived regulatory 
and legal uncertainties [42]
Reduction in the amount of 
clinical research [19,43]
FDA inspections FDA issues warning letters to 
Ranbaxy, Wockhardt, and 
Jubilant
Diminished confidence in 
Indian pharmaceutical 
industry
Quotes from FDA inspectors:
· “submitted untrue statements 
of material fact” [44]
· “concerns about integrity of all 
data” [45]
· “innocent ignorance, surprising 
sloppiness, malicious 
malfeasance” (HRPP 
conference, 2013)
Quintiles closing early-
phase unit
Collaboration with Apollo 
Hospitals, Hyderabad–
opened in 2010
One of only 2 early-phase 
units with international 
collaboration
Closed due to “challenging external business 
environment” [46]
Compensation schemes Key feature of activist and 
judicial demands: 
compensation for adverse 
events and lack of therapeutic 
effect; ethics committees 
responsible for determining 
liability in clinical trials
Initial compensation 
proposals prompt sponsor 
and investigator reluctance 
to conduct trials [18]
Unresolved issues: determination of adverse-
event causality; expectation of efficacy in 
clinical research; liability of placebo 
assignment; ethics committee resources and 
expertise to determine liability in clinical 
trials [38,30,47]
FDA, U.S. Food and Drug Administration; HPV, human papillomavirus; HRPP, human research protection program; NGO, non-governmental 
organization; NIH, U.S. National Institutes
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Table 3
AAHRPP Domains and Standards.
Domain Standards
Domain I: Organization
I-1: Organization has systemic and comprehensive human protection program
I-2: Adequate resources exist for program implementation
I-3: Transnational research activities are consistent across sites and respectful of local laws and 
cultural context
I-4: There is adequate response to research participant concerns
I-5: There are performance metrics and continuous process improvement
I-6: Financial conflicts of interest are identified and managed to minimize impact
I-7: There are policies and procedures governing use of investigational products
I-8: There is collaboration with public, industry, and public stakeholders
Domain II: IRB or EC
II-1: Structure and composition of IRB/EC is appropriate to the amount and nature of the 
research reviewed
II-2: IRB/EC evaluates each research protocol to ensure protection of participants
II-3: Approved protocols abide by applicable laws and regulations
II-4: Additional protection is provided to vulnerable research participants
II-5: IRB/EC maintains documentation of its activities
Domain III: Researcher and research staff
III-1: Adherence to ethical principles and rights and welfare of research participants are 
primary concerns when designing study
III-2: Researchers and staff meet all regulatory requirements and applicable laws
Adapted from: aahrpp.org [60]
EC, ethics committee; IRB, institutional review board.
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Table 4
PARTAKE Program Steps.
Steps Description
Step 1 PARTAKE survey of knowledge and 
perceptions of clinical research
Public survey to assess knowledge and perceptions of clinical research and inform 
education, public awareness, and participant protection programs
Step 2 Stakeholder collaborations Collaborations with industry, health care providers, academia, regulatory, patient 
advocacy groups, media, and the public at large [68]
Step 3 Development of awareness and engagement 
programs
Educational programs will be created to address the knowledge and awareness 
gaps identified in the survey
Step 4 Research on PARTAKE impact Research on impact of PARTAKE educational programs on public knowledge and 
awareness of clinical research
Step 5 Research on PARTAKE impact on clinical 
research
Research on impact of changing public knowledge, awareness, and attitudes on 
clinical research
Step 6 Enhancing clinical research programs Development of “participant protection” and “public-friendly” clinical research 
programs
Step 7 Development of an endorsement and rating/
scoring program
Establishing a rating/scoring program that includes representatives of all 
stakeholders involved in clinical research–to grade research operations for their 
“participant protection” and “public-friendly” properties and establish a process 
for endorsement and improvement of research operations
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Table 5
Challenges Facing PARTAKE Initiative and Proposed Solutions.
Challenges Solutions
Lack of public trust in investigators, 
sponsors, and regulators
Engage the public/community; invite patients/public to participate in clinical research decision-
making; empower, partner, and establish transparency in clinical research operations; establish 
research participant bill of rights
Fragmentation of the research 
environment
Establish a comprehensive public relations strategy; improve communication amongst stakeholders; 
use common language; engage the media; hold “open-house” activities; engage community 
advocates
Myths and misconceptions Increase awareness, educate, and reduce stigma; establish community advocates (members of the 
community who are informed about research and motivated to bridge the gap between the 
community and the research establishment)
Funding Establish a self-sustaining model; identify partners and sponsors; provide services to research sites 
and activist organizations; apply for grants from government, NGO, and industry groups
PARTAKE, Public Awareness of Research for Therapeutic Advancements through Knowledge and Empowerment; NGO, non-governmental 
organization
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